DARA Biosciences, Inc. recently entered into an exclusive distribution agreement with Seyer Pharmatec Inc. to sell and distribute the breast cancer product Soltamox in the Commonwealth of Puerto Rico. The company intends to launch Soltamox later in the year.
Soltamox is the first and only oral liquid formulation for breast cancer to be approved by the US Food & Drug Administration (FDA). Soltamox is marketed in the US by DARA. License to sell Soltamox in the US was granted by Rosemont Pharmaceuticals.
We note that many patients suffering from breast cancer face problems in swallowing pills. So an oral liquid formulation will be a convenient, comfortable and easy-to-swallow alternative for women with breast cancer.
In January, this year DARA acquired South Carolina-based specialty pharmaceutical company, Oncogenerix, Inc. Oncogenerix held an exclusive license for the US marketing rights to Soltamox from Rosemont. After Oncogenerix’ acquisition DARA now enjoys the rights to market the product in the US. Rosemont markets Soltamox in the UK and Ireland.
We remind investors that in June, this year, DARA launched its first product Bionect which treats skin irritation and burns associated with radiation therapy. The company introduced the product for the cancer care market across the US.
An important oncology candidate at DARA is KRN5500 (completed phase IIa study). The company’s pipeline also includes DB959 (type 2 diabetes).
Currently, we have a Neutral long-term stance on DARA. The company carries a Zacks #3 Rank (Hold rating) in the short run.